Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07721623
EARLY_PHASE1

The Efficacy of Carbitocin in Reduction of Blood Loss During Myomectomy

Sponsor: Alex Ekwueme Federal University Teaching Hospital

View on ClinicalTrials.gov

Summary

The uterine fibroids are the most common benign tumors found in the female reproductive system. Uterine fibroids commonly cause heavy menstrual periods. The prevalence of uterine fibroids is significantly affecting up to 70-80% of women by the age of 50, with an inconsistent impact on women of African origin. Carbitocin is a synthetic analogue of oxytocin which has a longer half-life than oxytocin. A Cochrane review and meta-analysis studies found that carbitocin reduced the use of additional uterotonics and transfusion. However, few of these studies was done during myomectomy.

Official title: A Randomized Controlled Trial of the Efficacy of Carbitocin in Reduction of Blood Loss During Myomectomy

Key Details

Gender

FEMALE

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

900

Start Date

2026-08-15

Completion Date

2028-08-14

Last Updated

2026-07-23

Healthy Volunteers

Yes

Interventions

DRUG

Carbetocin

Carbitocin is an oxytocid with longer half life